Non-Hodgkin Lymphoma Perspective

• Rick Simpson Oil: Cancer Cure or Pipe Dream? He's an Internet sensation, and many cancer patients swear by his eponymous oil. But clinicians and cannabis experts are waving red flags.
  Medscape Oncology, February 20, 2019
• Is Cell-Based Immunotherapy Entering the Mainstream?   Experts in cell-based therapies for cancer discuss opportunities and obstacles in their wider use beyond academic centers.
  Medscape Oncology, January 30, 2019
• CAR T Cell Therapy: 'It's the Real World Now'   Drs Jacobson, Miklos, and Maus unveil 'provocative and exciting' research at ASH 2018 in CAR T cell therapy.
  Medscape Oncology, January 24, 2019
• Venetoclax Shows Benefits Across a Range of Hematologic Cancers   From ASH 2018, Ann LaCasce and Jennifer Crombie from Dana-Farber discuss new trial data on venetoclax, a potent, selective inhibitor of BCL2.
  Medscape Oncology, December 27, 2018
• Oncologists' Off-Label Prescribing Pits Access Against Reimbursement Off-label prescribing in oncology is undergoing a change: Payers are more restrictive in their reimbursement for off-label uses, while oncologists are keen to provide access to new immunotherapies.
  Medscape Oncology, October 15, 2018
• Non-Hodgkin Lymphoma: Victory Lap   The team discusses the postinfusion period, when adverse effects are most common, and addresses remaining questions for the future of this innovative therapy.
  Medscape TV, September 26, 2018
• 5 Things to Know About Chronotherapy With the 2017 Nobel Prize in Medicine being awarded to research on circadian rhythms, the time has come to take a look at synchronizing chemotherapy with the body's natural clock. Here are five things you should know about chronotherapy.
  Medscape Oncology, August 17, 2018
• Non-Hodgkin Lymphoma: All Systems Go   The Moffitt team discusses patient referral and selection, as well as the extensive preparation candidates undergo before receiving CAR T-cell infusion.
  Medscape TV, July 20, 2018
• Cost Problem Only Getting Worse With IO Combos, Adjuvant Use   Drs Weber and Hamid discuss the increasing cost of immune-oncology therapy, particularly concerning as the number of patients using these agents in the adjuvant setting is likely to rise greatly.
  Medscape Oncology, June 21, 2018
• EHA 2018 Read clinically focused news coverage of key developments from EHA 2018
  Medscape Oncology, June 15, 2018
• IWMF 2018 Read clinically focused news coverage of key developments from IWMF 2018
  Medscape Oncology, May 22, 2018
• Non-Hodgkin Lymphoma: Test-Driving CAR T-Cell Therapy   CAR T-cell therapy is redirecting treatment and redefining the model of care for patients with relapsing lymphoma. The vanguard Moffitt team discusses the issues involved in this breakthrough therapy.
  Medscape TV, May 16, 2018
• 'Real World' CAR T Cells: Comparing and Using Approved Products   Drs Perales and Pasquini discuss the rapidly advancing field of CAR T and how patient safety and choice can be managed during these unprecedented times.
  Medscape Oncology, February 02, 2018
• Comparing CAR T-Cell Therapies in Lymphoma   Drs Ann LaCasce and Caron Jacobson on how these and other treatments may change your practice in the new year.
  Medscape Oncology, January 29, 2018
• Top News From ASH 2017: Slideshow Hot topics include moving to newer oral anticoagulants for cancer patients with VTE, plus practice-changing results in chronic lymphocytic leukemia, multiple myeloma, and Hodgkin's lymphoma.
  Medscape News Slideshows, December 22, 2017
• Safety With CAR T-Cell Therapy   Dr Stephan Grupp tells the 'inside story' of issues raised at the recent FDA Oncology Drug Advisory Committee meeting on CAR T-cell therapy.
  CHOP Expert Commentary, August 30, 2017
• Readers' Picks: Rising Stars of Healthcare Research Medscape readers nominate colleagues who represent America's pool of inspiring and pioneering researchers in medicine and healthcare.
  Medscape Features Slideshows, August 16, 2017
• European Hematology Association (EHA) 2017 Congress Read clinically focused news coverage of key developments from EHA 2017.
  theheart.org on Medscape, June 26, 2017
• Biomarkers to Determine Who Gets Checkpoint Inhibitors   Reviewing recent research, Dr Jeffrey Weber concludes that an amalgam of host- and tumor-related markers will be the best indication of which patients should receive checkpoint inhibitors.
  Medscape Oncology, April 03, 2017
• Top News From ASH 2016: Slideshow Practice-changing research in lymphoma and leukemia, plus growing excitement over two chimeric antigen receptor (CAR) T cell products, featured prominently at this year's meeting.
  Medscape News Slideshows, December 19, 2016